U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07191483) titled 'A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia' on Sept. 10.
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days.
Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose.
Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period.
P...